Beate Schmöele-Thoma

4.3k total citations
54 papers, 1.8k citations indexed

About

Beate Schmöele-Thoma is a scholar working on Epidemiology, Microbiology and Immunology. According to data from OpenAlex, Beate Schmöele-Thoma has authored 54 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Epidemiology, 17 papers in Microbiology and 6 papers in Immunology. Recurrent topics in Beate Schmöele-Thoma's work include Pneumonia and Respiratory Infections (44 papers), Respiratory viral infections research (37 papers) and Bacterial Infections and Vaccines (16 papers). Beate Schmöele-Thoma is often cited by papers focused on Pneumonia and Respiratory Infections (44 papers), Respiratory viral infections research (37 papers) and Bacterial Infections and Vaccines (16 papers). Beate Schmöele-Thoma collaborates with scholars based in United States, Germany and United Kingdom. Beate Schmöele-Thoma's co-authors include William C. Gruber, Daniel A. Scott, Emilio A. Emini, Alejandra Gurtman, Kathrin U. Jansen, Lisa A. Jackson, Martin van Cleeff, Deepthi Jayawardene, Robert W. Frenck and Richard N. Greenberg and has published in prestigious journals such as New England Journal of Medicine, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Beate Schmöele-Thoma

46 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Beate Schmöele-Thoma United States 22 1.6k 373 279 190 151 54 1.8k
Zitta Barrella Harboe Denmark 24 1.6k 1.0× 574 1.5× 321 1.2× 194 1.0× 138 0.9× 84 2.1k
Leszek Szenborn Poland 20 816 0.5× 423 1.1× 281 1.0× 94 0.5× 90 0.6× 125 1.3k
Jacek Wysocki Poland 22 1.3k 0.8× 476 1.3× 157 0.6× 174 0.9× 65 0.4× 121 1.6k
Nadia van Niekerk South Africa 19 1.2k 0.8× 193 0.5× 416 1.5× 125 0.7× 120 0.8× 38 1.5k
Lindsay R. Grant United States 22 857 0.6× 237 0.6× 225 0.8× 101 0.5× 48 0.3× 65 1.2k
Stanley Usen Gambia 13 717 0.5× 404 1.1× 143 0.5× 199 1.0× 96 0.6× 15 1.2k
Marie‐Pierre David Belgium 16 1.3k 0.8× 118 0.3× 280 1.0× 259 1.4× 140 0.9× 34 1.5k
Lorry G. Rubin United States 11 644 0.4× 600 1.6× 231 0.8× 71 0.4× 61 0.4× 18 1.1k
Rutger M. Schepp Netherlands 19 567 0.4× 175 0.5× 315 1.1× 154 0.8× 88 0.6× 37 931
María Teresa Valenzuela Chile 21 883 0.6× 665 1.8× 177 0.6× 112 0.6× 57 0.4× 67 1.3k

Countries citing papers authored by Beate Schmöele-Thoma

Since Specialization
Citations

This map shows the geographic impact of Beate Schmöele-Thoma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beate Schmöele-Thoma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beate Schmöele-Thoma more than expected).

Fields of papers citing papers by Beate Schmöele-Thoma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beate Schmöele-Thoma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beate Schmöele-Thoma. The network helps show where Beate Schmöele-Thoma may publish in the future.

Co-authorship network of co-authors of Beate Schmöele-Thoma

This figure shows the co-authorship network connecting the top 25 collaborators of Beate Schmöele-Thoma. A scholar is included among the top collaborators of Beate Schmöele-Thoma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beate Schmöele-Thoma. Beate Schmöele-Thoma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Madhi, Shabir A., Eric A. F. Simões, Nicola P. Klein, et al.. (2025). Dynamics of Respiratory Syncytial Virus Illness and Serology During Pregnancy and Infancy in the United States and South Africa. Open Forum Infectious Diseases. 12(7). ofaf386–ofaf386.
2.
Cai, Bing, Yili Chen, Beate Schmöele-Thoma, et al.. (2024). A Statistical Model to Predict Protection Against Infant Respiratory Syncytial Virus Disease Through Maternal Immunization. Vaccines. 12(12). 1351–1351.
3.
4.
Schmöele-Thoma, Beate, Agnieszka Zareba, Qin Jiang, et al.. (2022). Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study. New England Journal of Medicine. 386(25). 2377–2386. 79 indexed citations
5.
6.
Falsey, Ann R., Edward E. Walsh, Daniel A. Scott, et al.. (2021). Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine. The Journal of Infectious Diseases. 225(12). 2056–2066. 58 indexed citations
7.
Scott, Daniel A., et al.. (2020). Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence. Human Vaccines & Immunotherapeutics. 16(11). 2758–2772. 8 indexed citations
8.
Fletcher, Mark A., Jose A Suaya, Sally Jackson, et al.. (2020). Diabetes mellitus as a vaccine-effect modifier: a review. Expert Review of Vaccines. 19(5). 445–453. 20 indexed citations
9.
Schmöele-Thoma, Beate, Martin van Cleeff, Richard N. Greenberg, et al.. (2019). Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults. Human Vaccines & Immunotherapeutics. 15(3). 575–583. 6 indexed citations
10.
Juergens, Christine, James Trammel, Yasuko Shoji, et al.. (2018). Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations. Human Vaccines & Immunotherapeutics. 14(8). 1948–1956. 4 indexed citations
11.
Thompson, Allison, Nicola P. Klein, H. Jackson Downey, et al.. (2018). Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial. Human Vaccines & Immunotherapeutics. 15(2). 444–451. 16 indexed citations
12.
Suaya, Jose A, Qin Jiang, Daniel A. Scott, et al.. (2018). Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. Vaccine. 36(11). 1477–1483. 38 indexed citations
13.
Istúriz, Raúl, John M. McLaughlin, Vincenza Snow, et al.. (2017). Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age. Expert Review of Vaccines. 17(1). 45–55. 12 indexed citations
14.
Juergens, Christine, Vani Sundaraiyer, Mark Cutler, et al.. (2017). Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial. Human Vaccines & Immunotherapeutics. 13(9). 2065–2071. 12 indexed citations
15.
16.
Istúriz, Raúl, Beate Schmöele-Thoma, Daniel A. Scott, et al.. (2015). Pneumococcal conjugate vaccine use in adults. Expert Review of Vaccines. 15(3). 279–293. 15 indexed citations
17.
Juergens, Christine, Pierre J.T. De Villiers, Keymanthri Moodley, et al.. (2014). Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults. Human Vaccines & Immunotherapeutics. 10(5). 1343–1353. 31 indexed citations
18.
Greenberg, Richard N., Alejandra Gurtman, Robert W. Frenck, et al.. (2014). Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine–naïve adults 60–64 years of age. Vaccine. 32(20). 2364–2374. 115 indexed citations
19.
Glesby, Marshall J., Wendy Watson, Cynthia Brinson, et al.. (2014). Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine. The Journal of Infectious Diseases. 212(1). 18–27. 43 indexed citations
20.
Schwarz, Tino F., H. C. Rümke, C. Juergens, et al.. (2009). Safety and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Given Concomitantly with Trivalent Inactivated Influenza Vaccine in Healthy Adults. Journal of the American Geriatrics Society. 57.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zitta Barrella Harboe Breakdown of academic impact, for papers by Leszek Szenborn Breakdown of academic impact, for papers by Jacek Wysocki Breakdown of academic impact, for papers by Nadia van Niekerk Breakdown of academic impact, for papers by Lindsay R. Grant Breakdown of academic impact, for papers by Stanley Usen Breakdown of academic impact, for papers by Marie‐Pierre David Breakdown of academic impact, for papers by Lorry G. Rubin Breakdown of academic impact, for papers by Rutger M. Schepp Breakdown of academic impact, for papers by María Teresa Valenzuela
Rankless by CCL
2026